Prostate cancer (PC) remains the most commonly diagnosed malignant disease in men worldwide (121). At present, PD-1/PD-L1 immunocheckpoint inhibitors have brought significant clinical benefits to some patients with PC. Here, CD274 is linked to Familial prostate cancer.